Radioisotope Production (Indium-111)

In-111 decays by electron capture and gamma emission with a half-life of 2.8 days. It is typically produced in cyclotrons by bombarding cadmium-111 with protons. The resulting In-111 is then chemically incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of cyclotrons, cadmium-111 targets, and radiochemistry facilities. Logistical challenges include the transport and delivery of In-111 radiopharmaceuticals. Accessibility for developing countries is influenced by the high cost and technical expertise required for production and handling.

In-111 production and application are well-established, with widespread use in nuclear medicine.

In-111 is a radioactive isotope that emits gamma rays, requiring careful handling procedures and physical shielding to minimise radiation exposure.

All radioactive isotopes can be misused, and as such, robust security protocols around chain of custody, inventory management, and physical security are critical. 

Due to the absence of nuclear materials, IAEA safeguards are not applicable.